{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/MLTX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-29T17:02:34.690Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9772,"canonical_name":"MoonLake Immunotherapeutics","cik":"0001821586","uei":null,"lei":null,"duns":null,"ticker":"MLTX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":39},"count":39,"timeline":[{"ts":"2026-07-21","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-07-21","url_slug":"/sec/cik-0001821586/4/0001213900-26-080133","accession_number":"0001213900-26-080133","importance":30},{"ts":"2026-07-20","kind":"sec.insider.s","reporter":"Reich Kristian","title":"Chief Scientific Officer","shares":43700,"price_per_share":20.09,"usd_value":877933,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.877933},{"ts":"2026-07-20","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-07-20","url_slug":"/sec/cik-0001821586/4/0001213900-26-079376","accession_number":"0001213900-26-079376","importance":30},{"ts":"2026-07-15","kind":"sec.form144","reporter":"Reich Kristian","title":"Officer","shares":150000,"usd_value":2916000,"security_title":"Class A Ordinary","approx_sale_date":"2026-07-15","accession_number":"0001969223-26-000787","importance":40.5832},{"ts":"2026-07-15","kind":"sec.insider.s","reporter":"Reich Kristian","title":"Chief Scientific Officer","shares":16105,"price_per_share":20.01,"usd_value":322261,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.32226105},{"ts":"2026-07-15","kind":"sec.filing","form_type":"8-K","title":"8-K — MoonLake Immunotherapeutics — 2026-07-15","url_slug":"/sec/cik-0001821586/8-k/0001213900-26-078031","accession_number":"0001213900-26-078031","importance":35},{"ts":"2026-07-15","kind":"sec.filing","form_type":"144","title":"144 — MoonLake Immunotherapeutics — 2026-07-15","url_slug":"/sec/cik-0001821586/144/0001969223-26-000787","accession_number":"0001969223-26-000787","importance":30},{"ts":"2026-07-15","kind":"sec.insider.16105","reporter":"Reich Kristian","title":"Chief Scientific Officer","shares":16105,"price_per_share":20.01,"usd_value":322261,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":15.32226105},{"ts":"2026-07-13","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-07-13","url_slug":"/sec/cik-0001821586/4/0001213900-26-077564","accession_number":"0001213900-26-077564","importance":30},{"ts":"2026-07-10","kind":"sec.insider.s","reporter":"Santos da Silva Jorge","title":"Chief Executive Officer","shares":68289,"price_per_share":20.02,"usd_value":1367146,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":36.36714578},{"ts":"2026-07-09","kind":"sec.insider.s","reporter":"Santos da Silva Jorge","title":"Chief Executive Officer","shares":33936,"price_per_share":20.01,"usd_value":679059,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.67905936},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-07-02","url_slug":"/sec/cik-0001821586/4/0001213900-26-074964","accession_number":"0001213900-26-074964","importance":30},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Santos da Silva Jorge","title":"Chief Executive Officer","shares":47775,"price_per_share":20.03,"usd_value":956933,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.95693325},{"ts":"2026-06-30","kind":"sec.form144","reporter":"Santos da Silva Jorge","title":"Officer, CEO","shares":150000,"usd_value":3004500,"security_title":"Class A Ordinary","approx_sale_date":"2026-06-30","accession_number":"0001969223-26-000744","importance":40.6009},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — MoonLake Immunotherapeutics — 2026-06-30","url_slug":"/sec/cik-0001821586/144/0001969223-26-000744","accession_number":"0001969223-26-000744","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"SCHEDULE 13D/A","title":"SCHEDULE 13D/A — MoonLake Immunotherapeutics — 2026-06-29","url_slug":"/sec/cik-0001821586/schedule-13d-a/0000921895-26-001697","accession_number":"0000921895-26-001697","importance":70},{"ts":"2026-06-25","kind":"sec.filing","form_type":"8-K","title":"8-K — MoonLake Immunotherapeutics — 2026-06-25","url_slug":"/sec/cik-0001821586/8-k/0001213900-26-071721","accession_number":"0001213900-26-071721","importance":35},{"ts":"2026-06-24","kind":"sec.filing","form_type":"424B5","title":"424B5 — MoonLake Immunotherapeutics — 2026-06-24","url_slug":"/sec/cik-0001821586/424b5/0001213900-26-071586","accession_number":"0001213900-26-071586","importance":30},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-06-23","url_slug":"/sec/cik-0001821586/4/0001213900-26-071075","accession_number":"0001213900-26-071075","importance":30},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Bodenstedt Matthias","title":"Chief Financial Officer","shares":39120,"price_per_share":22.04,"usd_value":862205,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.8622048},{"ts":"2026-06-22","kind":"sec.filing","form_type":"8-K","title":"8-K — MoonLake Immunotherapeutics — 2026-06-22","url_slug":"/sec/cik-0001821586/8-k/0001213900-26-070362","accession_number":"0001213900-26-070362","importance":35},{"ts":"2026-06-22","kind":"sec.filing","form_type":"424B5","title":"424B5 — MoonLake Immunotherapeutics — 2026-06-22","url_slug":"/sec/cik-0001821586/424b5/0001213900-26-070709","accession_number":"0001213900-26-070709","importance":30},{"ts":"2026-06-18","kind":"sec.insider.s","reporter":"Bodenstedt Matthias","title":"Chief Financial Officer","shares":2794,"price_per_share":19.6,"usd_value":54762,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.0547624},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — Moukheibir Catherine — 2026-06-18","url_slug":"/sec/cik-0001772130/4/0001213900-26-070256","accession_number":"0001213900-26-070256","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-06-18","url_slug":"/sec/cik-0001821586/4/0001213900-26-070255","accession_number":"0001213900-26-070255","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-06-18","url_slug":"/sec/cik-0001821586/4/0001213900-26-070257","accession_number":"0001213900-26-070257","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-06-18","url_slug":"/sec/cik-0001821586/4/0001213900-26-070258","accession_number":"0001213900-26-070258","importance":30},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-06-18","url_slug":"/sec/cik-0001821586/4/0001213900-26-070259","accession_number":"0001213900-26-070259","importance":30},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Reich Kristian","title":"Chief Scientific Officer","shares":50000,"price_per_share":19.43,"usd_value":971500,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.9715},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Bodenstedt Matthias","title":"Chief Financial Officer","shares":15082,"price_per_share":19.68,"usd_value":296814,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.29681376},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-06-17","url_slug":"/sec/cik-0001821586/4/0001213900-26-069753","accession_number":"0001213900-26-069753","importance":30},{"ts":"2026-06-16","kind":"sec.insider.s","reporter":"Reich Kristian","title":"Chief Scientific Officer","shares":50000,"price_per_share":18.7,"usd_value":935000,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.935},{"ts":"2026-06-15","kind":"sec.form144","reporter":"Reich Kristian","title":"Officer","shares":150000,"usd_value":2850000,"security_title":"Class A Ordinary","approx_sale_date":"2026-06-15","accession_number":"0001969223-26-000703","importance":40.57},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Reich Kristian","title":"Chief Scientific Officer","shares":50000,"price_per_share":18.89,"usd_value":944500,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.9445},{"ts":"2026-06-15","kind":"sec.filing","form_type":"144","title":"144 — MoonLake Immunotherapeutics — 2026-06-15","url_slug":"/sec/cik-0001821586/144/0001969223-26-000703","accession_number":"0001969223-26-000703","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"8-K","title":"8-K — MoonLake Immunotherapeutics — 2026-06-09","url_slug":"/sec/cik-0001821586/8-k/0001213900-26-066821","accession_number":"0001213900-26-066821","importance":35},{"ts":"2026-06-01","kind":"sec.filing","form_type":"8-K","title":"8-K — MoonLake Immunotherapeutics — 2026-06-01","url_slug":"/sec/cik-0001821586/8-k/0001213900-26-063125","accession_number":"0001213900-26-063125","importance":35},{"ts":"2026-05-13","kind":"sec.filing","form_type":"4","title":"4 — MoonLake Immunotherapeutics — 2026-05-13","url_slug":"/sec/cik-0001821586/4/0001213900-26-055799","accession_number":"0001213900-26-055799","importance":30},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Bodenstedt Matthias","title":"Chief Financial Officer","shares":13653,"price_per_share":20.02,"usd_value":273333,"security_title":"Class A ordinary shares, par value $0.0001 per share","importance":35.27333306}]}